The results show that high expression of TCF7, AXIN2 and WIF1 all predict shorter relapse-free survival (RFS) in HER2-amplified breast cancer, but longer RFS in HER2-non-amplified disease. This evidence concerns the gene ERBB2 and breast carcinoma.